Beactica Extends Fragment-Based Discovery Research Services Agreement
"We are pleased to extend our collaboration with Janssen and look forward to further supporting their efforts to discover innovative medicines" said Beactica CEO, Dr Per Källblad. "The extension of our relationship testifies to the ability of our Sprint(TM) platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets".
Beactica initiated their first research services project with Janssen in early 2011.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel and mechanistically defined therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint(TM) platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The Company has its headquarter in Uppsala, Sweden. For more information, please visit www.beactica.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Research / Development":
Neue Herausforderungen bei IoT, Security und KI
Im Jahr 2018 werden anspruchsvolle IoT-Anwendungen die Grenzen der Datenverarbeitung weiter verschieben und IT-Sicherheitsforscher verstärkt selbst ins Visier geraten. Außerdem wird man maschinellem Lernen und künstlicher Intelligenz mit weniger Skepsis begegnen.Weiterlesen